Vg. Erwin et al., PHARMACOGENETICS OF COCAINE .2. MESOCORTICOLIMBIC AND STRIATAL DOPAMINE AND COCAINE RECEPTORS IN C57BL AND DBA MICE, Pharmacogenetics, 3(4), 1993, pp. 189-196
Studies were conducted to determine whether genetic differences in beh
avioural effects of cocaine in C57BL/6 and DBA/2 mice might be mediate
d by strain differences in dopamine and serotonin transporters and dop
amine D1 and D2 receptors in specific brain regions. Binding character
istics of [H-3]CFT, a cocaine analogue, in the presence of either GBR1
2909, a dopamine uptake blocker or fluoxetine, a serotonin uptake bloc
ker and binding of [H-3]-paroxetine, a specific serotonin uptake recep
tor antagonist, were evaluated. We observed regional differences in [H
-3]CFT binding parameters in the presence of GBR12909 or fluoxetine, b
ut no strain differences by brain region were observed. There were no
differences in [H-3]paroxetine binding characteristics between corresp
onding brain regions from C57BL and DBA/2 mice. The D1 antagonist, [H-
3]SCH23390 and the D2 ligands [H-3]sulpiride or [I-125]epiderpride wer
e used to determine dopamine receptor characteristics. Regional differ
ences were found in [H-3]SCH23390 and [H-3]sulpiride, with higher affi
nities and lower densities in frontal cortex compared to striatum; wit
h no differences in [H-3]SCH23390 binding in corresponding tissues fro
m C57BL and DBA/2 brains. There were strain-related differences in [H-
3]sulpiride and in [H-3]epidepride binding in striatal membranes with
higher densities in C57BL than in DBA/2. Our findings suggest striatal
D2 receptor differences are possibly involved in genetic differences
in cocaine-related behaviours.